Frontage Holdings Corp. (HK:1521)
:1521
Want to see HK:1521 full AI Analyst Report?
Top Page
Frontage Holdings Corp.
(1521)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$0.89
▼(-13.69% Downside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by mixed financial performance: long-term revenue expansion and manageable leverage are offset by margin compression, low returns on equity, and volatile/free-cash-flow weakness. Technicals are a significant drag with the stock trading below major moving averages and negative momentum indicators. Valuation is neutral with a mid-range P/E and no dividend yield support.
Positive Factors
Long-term revenue expansion
Sustained revenue expansion over multiple years indicates durable market demand and product adoption. A growing top line provides scale benefits, supports ongoing R&D and capacity investment, and gives management room to address margin pressure without eroding core business viability.
Negative Factors
Margin compression and low ROE
Meaningful decline in gross and net margins with ROE near 2% signals weakened earnings power and inefficient capital use. Persistently low margins constrain reinvestment and limit the firm’s ability to convert revenue gains into durable shareholder returns absent structural cost or pricing improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term revenue expansion
Sustained revenue expansion over multiple years indicates durable market demand and product adoption. A growing top line provides scale benefits, supports ongoing R&D and capacity investment, and gives management room to address margin pressure without eroding core business viability.
Read all positive factors
Frontage Holdings Corp. (1521) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.94B
Dividend YieldN/A
Average Volume (3M)468.13K
Price to Earnings (P/E)38.9
Beta (1Y)1.22
Revenue Growth0.61%
EPS Growth766.67%
CountryHK
Employees1,560
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,038,024,900
10 Day Avg. Volume431,000
30 Day Avg. Volume468,133
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.76
Price to Sales (P/S)1.03
P/FCF Ratio8.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$270.49M
Frontage Holdings Corp. Business Overview & Revenue Model
Company Description
Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such ...
How the Company Makes Money
null...
Frontage Holdings Corp. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 256.69M | 254.91M | 259.86M | 250.36M | 184.44M |
| Gross Profit | 69.20M | 69.81M | 78.39M | 89.19M | 66.70M |
| EBITDA | 41.86M | 35.37M | 45.02M | 54.10M | 42.56M |
| Net Income | 6.79M | 791.00K | 10.81M | 25.73M | 18.43M |
Balance Sheet | |||||
| Total Assets | 540.95M | 553.59M | 571.87M | 550.59M | 475.84M |
| Cash, Cash Equivalents and Short-Term Investments | 39.14M | 44.09M | 54.60M | 90.52M | 148.71M |
| Total Debt | 127.60M | 154.37M | 145.10M | 118.19M | 57.85M |
| Total Liabilities | 191.02M | 219.32M | 226.72M | 214.75M | 152.76M |
| Stockholders Equity | 346.74M | 333.00M | 342.50M | 333.08M | 319.84M |
Cash Flow | |||||
| Free Cash Flow | 32.27M | 14.75M | 18.59M | 14.78M | -5.83M |
| Operating Cash Flow | 43.93M | 40.64M | 39.74M | 62.44M | 44.55M |
| Investing Cash Flow | -13.85M | -41.48M | -87.63M | -147.91M | -107.44M |
| Financing Cash Flow | -37.36M | -10.22M | 12.91M | 30.66M | -5.54M |
Frontage Holdings Corp. Technical Analysis
Negative
1.03
Price Trends
1.03
Negative
1.04
Negative
1.16
Negative
Market Momentum
-0.04
Positive
34.34
Neutral
13.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1521, the sentiment is Negative. The current price of 1.03 is above the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.03, and below the 200-day MA of 1.16, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.34 is Neutral, neither overbought nor oversold. The STOCH value of 13.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1521.
Frontage Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$47.97B | 23.82 | 6.34% | 1.57% | 18.78% | 12.65% | |
68 Neutral | HK$51.05B | 22.45 | 11.22% | 1.04% | 16.83% | -8.65% | |
64 Neutral | HK$137.23B | 24.33 | 10.55% | ― | 16.79% | 47.14% | |
62 Neutral | HK$28.49B | -6.49 | -12.75% | ― | ― | ― | |
58 Neutral | HK$20.67B | 25.33 | 11.29% | ― | 48.38% | ― | |
52 Neutral | HK$1.94B | 38.94 | 1.98% | ― | 0.61% | 766.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:1521
Frontage Holdings Corp.
0.95
-0.18
-15.93%
HK:1548
Genscript Biotech
13.09
2.15
19.65%
HK:2269
Wuxi Biologics (Cayman)
33.14
8.44
34.17%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
18.28
4.86
36.19%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
50.60
36.32
254.34%
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
92.40
27.42
42.20%
Frontage Holdings Corp. Corporate Events
Frontage Swings to Profit on Revenue Growth and Acquisition Boost in Q1 2026
Apr 28, 2026
Frontage Holdings reported a sharp turnaround in the first quarter of 2026, posting unaudited net profit of about US$2.9 million on revenue of US$67.9 million, compared with a loss a year earlier as sales rose 18.9%. Adjusted net profit surged 212...
Frontage Holdings Sets 2026 AGM to Seek Mandates on Share Buybacks and Issuance
Apr 28, 2026
Frontage Holdings Corporation has called its annual general meeting for 2 June 2026 in Shanghai, where shareholders will review and adopt the audited consolidated financial statements and directors’ and auditor’s reports for the year e...
Frontage Holdings Lifts 2025 Profit on Strong Margins Despite Flat Revenue
Mar 30, 2026
Frontage Holdings reported broadly flat 2025 revenue of US$256.7 million, but significantly improved profitability, with EBITDA rising 8.0% and net profit jumping to US$6.8 million from US$0.6 million a year earlier. Adjusted net profit increased ...
Frontage Holdings Sets Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 17, 2026
Frontage Holdings Corporation has scheduled a board meeting for March 30, 2026 to review and approve its annual results for the year ended December 31, 2025. At the same meeting, the board will also consider whether to recommend a final dividend, ...
Frontage Holdings Completes Major Connected Acquisition and Consolidates New Subsidiary
Mar 3, 2026
Frontage Holdings Corporation has completed its previously announced acquisition of the entire issued share capital of a target company, following shareholder approval at an extraordinary general meeting. The deal, classified as a major and connec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.